{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:02:46Z","timestamp":1793678566335,"version":"4.5.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH115426"],"award-info":[{"award-number":["MH115426"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Molecular Autism"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Research evidence accumulated in the past years in both rodent and human models for autism spectrum disorders (ASD) have established insulin-like growth factor 1 (IGF-1) as one of the most promising ASD therapeutic interventions to date. ASD is phenotypically and etiologically heterogeneous, making it challenging to uncover the underlying genetic and cellular pathophysiology of the condition; and to efficiently design drugs with widespread clinical benefits. While IGF-1 effects have been comprehensively studied in the literature, how IGF-1 activity may lead to therapeutic recovery in the ASD context is still largely unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, we used a previously characterized neuronal population derived from induced pluripotent stem cells (iPSC) from neurotypical controls and idiopathic ASD individuals to study the transcriptional signature of acutely and chronically IGF-1-treated cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We present a comprehensive list of differentially regulated genes and molecular interactions resulting from IGF-1 exposure in developing neurons from controls and ASD individuals. Our results indicate that IGF-1 treatment has a different impact on neurons from ASD patients compared to controls. Response to IGF-1 treatment in neurons derived from ASD patients was heterogeneous and correlated with IGF-1 receptor expression, indicating that IGF-1 response may have responder and non-responder distinctions across cohorts of ASD patients. Our results suggest that caution should be used when predicting the effect of IGF-1 treatment on ASD patients using neurotypical controls. Instead, IGF-1 response should be studied in the context of ASD patients\u2019 neural cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Limitations<\/jats:title><jats:p>The limitation of our study is that our cohort of eight sporadic ASD individuals is comorbid with macrocephaly\u00a0in childhood. Future studies will address weather downstream transcriptional response of IGF-1 is comparable in non-macrocephalic ASD cohorts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The results presented in this study provide an important resource for researchers in the ASD field and underscore the necessity of using ASD patient lines to explore ASD neuronal-specific responses to drugs such as IGF-1. This study further helps to identify candidate pathways and targets for effective clinical intervention and may help to inform clinical trials in the future.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13229-020-00359-w","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T15:04:32Z","timestamp":1593183872000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["IGF-1 treatment causes unique transcriptional response in neurons from individuals with idiopathic autism"],"prefix":"10.1186","volume":"11","author":[{"given":"Sara B.","family":"Linker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana P. D.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0449-9051","authenticated-orcid":false,"given":"Maria C.","family":"Marchetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"issue":"2","key":"359_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6802a1","volume":"68","author":"DL Christensen","year":"2019","unstructured":"Christensen DL, Maenner MJ, Bilder D, Constantino JN, Daniels J, Durkin MS, et al. Prevalence and characteristics of autism spectrum disorder among children aged 4 years\u2014early autism and developmental disabilities monitoring network, seven sites, United States, 2010, 2012, and 2014. MMWR Surveill Summ. 2019;68(2):1\u201319.","journal-title":"MMWR Surveill Summ"},{"issue":"7526","key":"359_CR2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nature13772","volume":"515","author":"S De Rubeis","year":"2014","unstructured":"De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE, et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature. 2014;515(7526):209\u201315.","journal-title":"Nature."},{"issue":"5","key":"359_CR3","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ajhg.2014.03.018","volume":"94","author":"D Pinto","year":"2014","unstructured":"Pinto D, Delaby E, Merico D, Barbosa M, Merikangas A, Klei L, et al. Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. Am J Hum Genet. 2014;94(5):677\u201394.","journal-title":"Am J Hum Genet"},{"issue":"11","key":"359_CR4","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/nn.4420","volume":"19","author":"Y Sztainberg","year":"2016","unstructured":"Sztainberg Y, Zoghbi HY. Lessons learned from studying syndromic autism spectrum disorders. Nat Neurosci. 2016;19(11):1408\u201317.","journal-title":"Nat Neurosci"},{"issue":"2","key":"359_CR5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tins.2013.11.005","volume":"37","author":"N Krumm","year":"2014","unstructured":"Krumm N, O'Roak BJ, Shendure J, Eichler EE. A de novo convergence of autism genetics and molecular neuroscience. Trends Neurosci. 2014;37(2):95\u2013105.","journal-title":"Trends Neurosci"},{"issue":"7526","key":"359_CR6","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nature13908","volume":"515","author":"I Iossifov","year":"2014","unstructured":"Iossifov I, O'Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D, et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature. 2014;515(7526):216\u201321.","journal-title":"Nature."},{"key":"359_CR7","first-page":"601","volume":"10","author":"A Ansel","year":"2016","unstructured":"Ansel A, Rosenzweig JP, Zisman PD, Melamed M, Gesundheit B. Variation in gene expression in autism spectrum disorders: an extensive review of transcriptomic studies. Front Neurosci. 2016;10:601.","journal-title":"Front Neurosci"},{"key":"359_CR8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.neubiorev.2016.01.001","volume":"63","author":"J Costales","year":"2016","unstructured":"Costales J, Kolevzon A. The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders. Neurosci Biobehav Rev. 2016;63:207\u201322.","journal-title":"Neurosci Biobehav Rev"},{"key":"359_CR9","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3389\/fnins.2016.00450","volume":"10","author":"C Vahdatpour","year":"2016","unstructured":"Vahdatpour C, Dyer AH, Tropea D. Insulin-like growth factor 1 and related compounds in the treatment of childhood-onset neurodevelopmental disorders. Front Neurosci. 2016;10:450.","journal-title":"Front Neurosci"},{"issue":"2","key":"359_CR10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/gbb.12340","volume":"16","author":"TL Wise","year":"2017","unstructured":"Wise TL. Changes in insulin-like growth factor signaling alter phenotypes in Fragile X Mice. Genes Brain Behav. 2017;16(2):241\u20139.","journal-title":"Genes Brain Behav"},{"issue":"1","key":"359_CR11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/2040-2392-4-9","volume":"4","author":"O Bozdagi","year":"2013","unstructured":"Bozdagi O, Tavassoli T, Buxbaum JD. Insulin-like growth factor-1 rescues synaptic and motor deficits in a mouse model of autism and developmental delay. Mol Autism. 2013;4(1):9.","journal-title":"Mol Autism"},{"issue":"1","key":"359_CR12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12017-015-8341-2","volume":"17","author":"RM Deacon","year":"2015","unstructured":"Deacon RM, Glass L, Snape M, Hurley MJ, Altimiras FJ, Biekofsky RR, et al. NNZ-2566, a novel analog of (1-3) IGF-1, as a potential therapeutic agent for fragile X syndrome. NeuroMolecular Med. 2015;17(1):71\u201382.","journal-title":"NeuroMolecular Med"},{"issue":"6","key":"359_CR13","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1073\/pnas.0812394106","volume":"106","author":"D Tropea","year":"2009","unstructured":"Tropea D, Giacometti E, Wilson NR, Beard C, McCurry C, Fu DD, et al. Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci U S A. 2009;106(6):2029\u201334.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"27","key":"359_CR14","doi-asserted-by":"crossref","first-page":"9941","DOI":"10.1073\/pnas.1311685111","volume":"111","author":"J Castro","year":"2014","unstructured":"Castro J, Garcia RI, Kwok S, Banerjee A, Petravicz J, Woodson J, et al. Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett Syndrome. Proc Natl Acad Sci U S A. 2014;111(27):9941\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7475","key":"359_CR15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nature12618","volume":"503","author":"A Shcheglovitov","year":"2013","unstructured":"Shcheglovitov A, Shcheglovitova O, Yazawa M, Portmann T, Shu R, Sebastiano V, et al. SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients. Nature. 2013;503(7475):267\u201371.","journal-title":"Nature."},{"issue":"6","key":"359_CR16","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/mp.2016.95","volume":"22","author":"MC Marchetto","year":"2017","unstructured":"Marchetto MC, Belinson H, Tian Y, Freitas BC, Fu C, Vadodaria K, et al. Altered proliferation and networks in neural cells derived from idiopathic autistic individuals. Mol Psychiatry. 2017;22(6):820\u201335.","journal-title":"Mol Psychiatry"},{"issue":"4","key":"359_CR17","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.cell.2010.10.016","volume":"143","author":"MC Marchetto","year":"2010","unstructured":"Marchetto MC, Carromeu C, Acab A, Yu D, Yeo GW, Mu Y, et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell. 2010;143(4):527\u201339.","journal-title":"Cell."},{"issue":"12","key":"359_CR18","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1073\/pnas.1311141111","volume":"111","author":"OS Khwaja","year":"2014","unstructured":"Khwaja OS, Ho E, Barnes KV, O'Leary HM, Pereira LM, Finkelstein Y, et al. Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proc Natl Acad Sci U S A. 2014;111(12):4596\u2013601.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"359_CR19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/2040-2392-5-54","volume":"5","author":"A Kolevzon","year":"2014","unstructured":"Kolevzon A, Bush L, Wang AT, Halpern D, Frank Y, Grodberg D, et al. A pilot controlled trial of insulin-like growth factor-1 in children with Phelan-McDermid syndrome. Mol Autism. 2014;5(1):54.","journal-title":"Mol Autism"},{"issue":"1","key":"359_CR20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neulet.2012.05.029","volume":"520","author":"AP Corvin","year":"2012","unstructured":"Corvin AP, Molinos I, Little G, Donohoe G, Gill M, Morris DW, et al. Insulin-like growth factor 1 (IGF1) and its active peptide (1-3)IGF1 enhance the expression of synaptic markers in neuronal circuits through different cellular mechanisms. Neurosci Lett. 2012;520(1):51\u20136.","journal-title":"Neurosci Lett"},{"key":"359_CR21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.neuroscience.2016.03.056","volume":"325","author":"AH Dyer","year":"2016","unstructured":"Dyer AH, Vahdatpour C, Sanfeliu A, Tropea D. The role of insulin-like growth factor 1 (IGF-1) in brain development, maturation and neuroplasticity. Neuroscience. 2016;325:89\u201399.","journal-title":"Neuroscience."},{"key":"359_CR22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijdevneu.2014.03.006","volume":"35","author":"J Chen","year":"2014","unstructured":"Chen J, Alberts I, Li X. Dysregulation of the IGF-I\/PI3K\/AKT\/mTOR signaling pathway in autism spectrum disorders. Int J Dev Neurosci. 2014;35:35\u201341.","journal-title":"Int J Dev Neurosci"},{"issue":"5495","key":"359_CR23","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1126\/science.290.5495.1364","volume":"290","author":"AE El-Husseini","year":"2000","unstructured":"El-Husseini AE, Schnell E, Chetkovich DM, Nicoll RA, Bredt DS. PSD-95 involvement in maturation of excitatory synapses. Science. 2000;290(5495):1364\u20138.","journal-title":"Science."},{"issue":"4","key":"359_CR24","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00018-002-8451-5","volume":"59","author":"A Ferreira","year":"2002","unstructured":"Ferreira A, Rapoport M. The synapsins: beyond the regulation of neurotransmitter release. Cell Mol Life Sci. 2002;59(4):589\u201395.","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"359_CR25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nrn2540","volume":"10","author":"W Feng","year":"2009","unstructured":"Feng W, Zhang M. Organization and dynamics of PDZ-domain-related supramodules in the postsynaptic density. Nat Rev Neurosci. 2009;10(2):87\u201399.","journal-title":"Nat Rev Neurosci"},{"key":"359_CR26","doi-asserted-by":"crossref","unstructured":"Marchetto MC, Belinson H, Tian Y, Freitas BC, Fu C, Vadodaria KC, et al. Altered proliferation and networks in neural cells derived from idiopathic autistic individuals. Mol Psychiatry. 2016.","DOI":"10.1038\/mp.2016.95"},{"issue":"3","key":"359_CR27","first-page":"18","volume":"2","author":"AWM Liaw","year":"2002","unstructured":"Liaw AWM. Classification and Regression by randomForest. R News. 2002;2(3):18\u201322.","journal-title":"R News"},{"issue":"4","key":"359_CR28","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/jmedgenet-2015-103500","volume":"53","author":"J Koch","year":"2016","unstructured":"Koch J, Feichtinger RG, Freisinger P, Pies M, Schrodl F, Iuso A, et al. Disturbed mitochondrial and peroxisomal dynamics due to loss of MFF causes Leigh-like encephalopathy, optic atrophy and peripheral neuropathy. J Med Genet. 2016;53(4):270\u20138.","journal-title":"J Med Genet"},{"key":"359_CR29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13072-016-0106-0","volume":"9","author":"AS Labade","year":"2016","unstructured":"Labade AS, Karmodiya K, Sengupta K. HOXA repression is mediated by nucleoporin Nup93 assisted by its interactors Nup188 and Nup205. Epigenetics Chromatin. 2016;9:54.","journal-title":"Epigenetics Chromatin"},{"issue":"5","key":"359_CR30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrg3897","volume":"16","author":"MJ Lyst","year":"2015","unstructured":"Lyst MJ, Bird A. Rett syndrome: a complex disorder with simple roots. Nat Rev Genet. 2015;16(5):261\u201375.","journal-title":"Nat Rev Genet"},{"issue":"Suppl 2","key":"359_CR31","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1038\/sj.mp.4001171","volume":"7","author":"M Evers","year":"2002","unstructured":"Evers M, Cunningham-Rundles C, Hollander E. Heat shock protein 90 antibodies in autism. Mol Psychiatry. 2002;7(Suppl 2):S26\u20138.","journal-title":"Mol Psychiatry"},{"issue":"15","key":"359_CR32","doi-asserted-by":"crossref","first-page":"E3559","DOI":"10.1073\/pnas.1717082115","volume":"115","author":"MA Lin","year":"2018","unstructured":"Lin MA, Cannon SC, Papazian DM. Kv4.2 autism and epilepsy mutation enhances inactivation of closed channels but impairs access to inactivated state after opening. Proc Natl Acad Sci U S A. 2018;115(15):E3559\u2013E68.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"359_CR33","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1093\/hmg\/ddu056","volume":"23","author":"H Lee","year":"2014","unstructured":"Lee H, Lin MC, Kornblum HI, Papazian DM, Nelson SF. Exome sequencing identifies de novo gain of function missense mutation in KCND2 in identical twins with autism and seizures that slows potassium channel inactivation. Hum Mol Genet. 2014;23(13):3481\u20139.","journal-title":"Hum Mol Genet"},{"key":"359_CR34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.bbr.2012.12.015","volume":"251","author":"B Greco","year":"2013","unstructured":"Greco B, Manago F, Tucci V, Kao HT, Valtorta F, Benfenati F. Autism-related behavioral abnormalities in synapsin knockout mice. Behav Brain Res. 2013;251:65\u201374.","journal-title":"Behav Brain Res"},{"issue":"7646","key":"359_CR35","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nature21678","volume":"543","author":"V Krishnan","year":"2017","unstructured":"Krishnan V, Stoppel DC, Nong Y, Johnson MA, Nadler MJ, Ozkaynak E, et al. Autism gene Ube3a and seizures impair sociability by repressing VTA Cbln1. Nature. 2017;543(7646):507\u201312.","journal-title":"Nature."},{"issue":"4","key":"359_CR36","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/npp.2013.274","volume":"39","author":"G Karvat","year":"2014","unstructured":"Karvat G, Kimchi T. Acetylcholine elevation relieves cognitive rigidity and social deficiency in a mouse model of autism. Neuropsychopharmacology. 2014;39(4):831\u201340.","journal-title":"Neuropsychopharmacology."},{"issue":"1","key":"359_CR37","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/2040-2392-4-48","volume":"4","author":"V Warrier","year":"2013","unstructured":"Warrier V, Baron-Cohen S, Chakrabarti B. Genetic variation in GABRB3 is associated with Asperger syndrome and multiple endophenotypes relevant to autism. Mol Autism. 2013;4(1):48.","journal-title":"Mol Autism"},{"issue":"5","key":"359_CR38","doi-asserted-by":"crossref","first-page":"e10534","DOI":"10.1371\/journal.pone.0010534","volume":"5","author":"MT Handley","year":"2010","unstructured":"Handley MT, Lian LY, Haynes LP, Burgoyne RD. Structural and functional deficits in a neuronal calcium sensor-1 mutant identified in a case of autistic spectrum disorder. PLoS One. 2010;5(5):e10534.","journal-title":"PLoS One"},{"key":"359_CR39","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1186\/1471-2105-11-485","volume":"11","author":"MP Cox","year":"2010","unstructured":"Cox MP, Peterson DA, Biggs PJ. SolexaQA: At-a-glance quality assessment of Illumina second-generation sequencing data. BMC Bioinformatics. 2010;11:485.","journal-title":"BMC Bioinformatics"},{"issue":"5","key":"359_CR40","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nbt.3519","volume":"34","author":"NL Bray","year":"2016","unstructured":"Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol. 2016;34(5):525\u20137.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"359_CR41","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139\u201340.","journal-title":"Bioinformatics."},{"key":"359_CR42","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.","journal-title":"BMC Bioinformatics"},{"issue":"9","key":"359_CR43","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/bioinformatics\/btm069","volume":"23","author":"W Stacklies","year":"2007","unstructured":"Stacklies W, Redestig H, Scholz M, Walther D, Selbig J. pcaMethods\u2014a bioconductor package providing PCA methods for incomplete data. Bioinformatics. 2007;23(9):1164\u20137.","journal-title":"Bioinformatics."}],"container-title":["Molecular Autism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13229-020-00359-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13229-020-00359-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13229-020-00359-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T13:55:34Z","timestamp":1667138134000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularautism.biomedcentral.com\/articles\/10.1186\/s13229-020-00359-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["359"],"URL":"https:\/\/doi.org\/10.1186\/s13229-020-00359-w","relation":{},"ISSN":["2040-2392"],"issn-type":[{"value":"2040-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,26]]},"assertion":[{"value":"12 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work has been approved by the Salk Institute\u2019s Institutional Review Board. The study presented here is not considered human subjects research because the specimens or data were not collected specifically for the study presented and no one on the study team has access to the subject identifiers linked to the specimens or data.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}